Blood Cancer United Pilot Clinical Trial Grants
Over the past 10 years, Waldenstrom macroglobulinemia (WM) patients have benefited from the development of novel agents used for other hematological cancers, such as covalent and non-covalent BTK inhibitors (BTKis) and BCL2 antagonists, which had received prior FDA approvals for other indications.
This document is the 2026 Request for Proposals for the International Waldenstrom Macroglobulinemia Foundation (IWMF) – Blood Cancer United Pilot Clinical Trial Grants Initiative. It outlines the program background, objectives, grant structure, application procedures, eligibility, and review criteria for investigator-initiated studies aimed at advancing novel therapeutic strategies for Waldenstrom macroglobulinemia (WM). The initiative focuses on innovative clinical studies using new agents, combination therapies, and immunotherapies with the goal of improving patient outcomes and potentially achieving a functional cure for WM.
The claim illustrates the clinical challenge that despite advances, WM patients still face limited complete response rates and resistance to existing therapies, underscoring the need for novel treatment approaches. This sets the rationale for the IWMF grant to support innovative clinical trials that could lead to improved outcomes and eventual cure.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia